Endpoints News |
Lexicon 3-for-3 in PhIII for a new diabetes pill, racking up a clean sweep under $1.7B Sanofi pact
Endpoints News Investigators tested this add-on drug in 1,402 patients with A1C levels between 7% and 11%, with a 400 mg dose beating a placebo in pushing a significant number of patients below the 7 mark — the magic number for glycemic control in diabetes. But we ... Lexicon Pharma's sotagliflozin successful in third late-stage diabetes study Lexicon Pharma's (LXRX) Phase 3 inTandem3 Study For Sotagliflozin in Patients With Type 1 Diabetes Meets Primary ... |
Social Plugin